Solid Biosciences Q2 Loss Widens to $54.8M, Cash Runway Extended to Mid-2028
SLDB has more than doubled off its 52-week low of $3.79 on light trading volume (0.3× avg).
Summary
Solid Biosciences reported a Q2 net loss of $54.8 million, wider than the prior year, driven by increased R&D spending on its gene therapy programs. The company ended the quarter with $377.7 million in cash, which it expects will fund operations into mid-2028. Key catalysts ahead include an FDA meeting on the SGT-003 accelerated approval pathway in late Q4 2026 and initial Phase 1b data for SGT-212 in Q1 2027. The higher burn rate reflects advancing clinical trials, but the strong cash position provides a multi-year runway.
At the time of this announcement, SLDB was trading at $8.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $857.5M. The 52-week trading range was $3.79 to $11.45. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.